CSF and Plasma Biomarkers in Patients With Iatrogenic Cerebral Amyloid Angiopathy DOI
Giuliana Pollaci, Antonella Potenza, Gemma Gorla

и другие.

Neurology, Год журнала: 2024, Номер 103(8)

Опубликована: Сен. 16, 2024

Recently, a subset of patients affected by cerebral amyloid angiopathy (CAA) distinguished atypical juvenile onset and hypothesized iatrogenic origin (iatrogenic CAA, iCAA) has emerged. β-Amyloid (Aβ) accumulation evidenced PET positivity or CSF Aβ decrease was included in the iCAA diagnostic criteria. Conversely, criteria for sporadic CAA (sCAA) do not involve biomarker analysis. The aim this study to assess plasma levels tau sCAA cohorts.

Язык: Английский

Cerebral Amyloid Angiopathy Related Inflammation: A Single-Center Case Series Analysis DOI Creative Commons
Syed Zahid Ali, Hanah Alley,

James T. Johnson

и другие.

Brain Sciences, Год журнала: 2025, Номер 15(5), С. 472 - 472

Опубликована: Апрель 29, 2025

Cerebral amyloid angiopathy-related inflammation (CAA-RI) is a rare subtype of cerebral angiopathy (CAA), which presents mostly as subacute and reversible encephalopathy. Primary symptoms include behavioral changes cognitive decline in the form rapidly progressive dementia, headache, seizures, focal neurological deficits. It can also manifest varied range typical atypical presentations. Misdiagnosis common because it shares with other infectious, ischemic autoimmune pathologies there significant overlap MRI findings. Gold standard diagnosis requires brain biopsy appropriate clinical setting, but diagnostic criteria established for probable possible CAA-RI using findings absence inflammatory, infectious or processes. Immunomodulatory therapy mainstay treatment, variable response. We present case series three patients highlighting disease course, neuroradiological manifestation, treatment response, outcomes. provide literature review to increase insight into this pathology. Early prompt initiation immunosuppressive beneficial most cases.

Язык: Английский

Процитировано

0

CSF and Plasma Biomarkers in Patients With Iatrogenic Cerebral Amyloid Angiopathy DOI
Giuliana Pollaci, Antonella Potenza, Gemma Gorla

и другие.

Neurology, Год журнала: 2024, Номер 103(8)

Опубликована: Сен. 16, 2024

Recently, a subset of patients affected by cerebral amyloid angiopathy (CAA) distinguished atypical juvenile onset and hypothesized iatrogenic origin (iatrogenic CAA, iCAA) has emerged. β-Amyloid (Aβ) accumulation evidenced PET positivity or CSF Aβ decrease was included in the iCAA diagnostic criteria. Conversely, criteria for sporadic CAA (sCAA) do not involve biomarker analysis. The aim this study to assess plasma levels tau sCAA cohorts.

Язык: Английский

Процитировано

0